Alnylam Pharmaceuticals, Inc. (ALNY)
305.54
-8.25
(-2.63%)
USD |
NASDAQ |
Apr 24, 16:00
307.80
+2.26
(+0.74%)
After-Hours: 20:00
Alnylam Pharmaceuticals EPS Diluted (Quarterly) : 1.368 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Pfizer Inc. | -0.2898 |
| Gilead Sciences, Inc. | 1.742 |
| Ionis Pharmaceuticals, Inc. | -1.414 |
| Eli Lilly & Co. | 7.024 |
| Sarepta Therapeutics, Inc. | -3.934 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 186.42M |
| Revenue (Quarterly) | 1.097B |
| Total Expenses (Quarterly) | 910.61M |
| Enterprise Value | 40.58B |
| Gross Profit Margin (Quarterly) | 75.60% |
| Profit Margin (Quarterly) | 16.99% |
| Earnings Yield | 0.74% |
| Operating Earnings Yield | 1.23% |
| Normalized Earnings Yield | 0.8149 |